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A B S T R A C T
Background: Current UK and European guidelines recommend anticoagulated patients prescribed warfarin with
time in therapeutic range (TTR)< 65% be considered for DOAC therapy. There has been considerable concern
that adherence with DOACs may be poor compared with warfarin. Little is known about the patient experience
of switching from warfarin to DOAC and how patients manage their DOAC long term. Our aim was to conduct
focus groups exploring patient's previous experiences with warfarin, their current experience with DOACs, their
adherence to DOACs and the long-term service provision they envisage.
Methods: Patients enrolled on the Switching Study who had been switched from warfarin to a DOAC> 1 year
previously were invited to participate in focus groups. Two focus groups for atrial ﬁbrillation (AF) and two for
secondary prevention of venous thromboembolism (VTE) patients were held at anticoagulation clinics in South
London, UK. Data was analysed using framework analysis to extract dominant themes.
Results: Five VTE patients and 15 AF patients attended the focus groups. Dominant themes that emerged were:
indication speciﬁc anticoagulation prioritisation, warfarin as a necessary inconvenience, DOACs as the antic-
oagulant of choice, concerns regarding DOAC monitoring, high adherence to DOACs and desire for long-term
access to specialist anticoagulation services.
Discussion: VTE patients prioritised anticoagulation over other therapies whereas AF patients did not. All par-
ticipants reported high levels of adherence to DOACs. Patients derived conﬁdence from long-term management
in specialist anticoagulation clinics stating a preference to be managed in such a service.
1. Introduction
Since their introduction into clinical practice, direct oral antic-
oagulants (DOACs) are being increasingly prescribed for stroke pre-
vention in atrial ﬁbrillation (AF) and the treatment and secondary
prevention of venous thromboembolism (VTE) [1]. In phase III clinical
trials apixaban dabigatran, edoxaban and rivaroxaban were shown to
be at least non-inferior to traditional vitamin-K antagonists (VKAs) such
as warfarin [2–12]. Relative advantages of DOACs compared to VKAs
include: a predictable pharmacokinetic proﬁle enabling ﬁxed dosing
and infrequent laboratory monitoring, limited drug- drug interactions
and insigniﬁcant drug- food interactions [13]. However, although
DOACs may have a lower burden on both patients and healthcare
providers, they present new challenges for anticoagulation services.
With VKAs, patients are routinely required to undergo laboratory
monitoring for international normalised ratio (INR) tests to ensure safe
and eﬀective care. This provides patients with the opportunity to
monitor their results over time, providing direct feedback on their
medicines taking behaviour. This is not possible with DOACs. Out of
range INR results can be investigated for underlying causes in colla-
boration with anticoagulant clinic staﬀ; oﬀering opportunities for pa-
tients to discuss issues surrounding their VKA management with a
specialist, allowing for educational opportunities as well as timely re-
solution of any problems. One such issue is medication adherence.
Frequent INR monitoring provides an indication to clinicians regarding
patient adherence. Opportunities arise to broach issues surrounding not
only adherence but also the impact of the disease and the beneﬁts of
therapy. As this model of care is not required with DOACs, there is
signiﬁcant concern that this lack of routine monitoring and regular
engagement with anticoagulation services may lead to worse adherence
to DOACs compared to VKAs [14–16].
Whilst some work has been done to describe adherence to DOACs
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over recent years [17,18], including amongst those that have switched
therapy from VKA to DOAC [19], there is very little narrative evidence
exploring adherence to DOACs and the patient's journey from initiation
to discharge from secondary care services and beyond.
The new age of DOACs presents a signiﬁcant paradigm shift for
practitioners and patients alike. In the UK and Europe, guidelines re-
commend those with poor INR control as measured by time in ther-
apeutic range (TTR)< 65% should be considered for alternative an-
ticoagulation therapy [20,21]. Special focus is therefore required for
those who are switched from VKAs to DOACs as their experience with
VKAs may lead to expectations as to what anticoagulation therapy is
and what it requires.
Amongst those prescribed VKAs, research has demonstrated that
although many patients ﬁnd monitoring burdensome [22], a signiﬁcant
number derived conﬁdence from monitoring, reassuring them of their
control over their illness with many claiming they would be appre-
hensive about anticoagulants that required no such monitoring
[23–25]. Research also shows patients rely heavily on the availability of
specialist anticoagulation staﬀ to manage their VKA therapy [23].
Regular access is not available within the current UK model of care
where DOACs will be managed in primary care and patients only gain
access to specialists following referral. Studies assessing patient pre-
ferences for ideal anticoagulants demonstrated patients prefer regimes
more akin to DOACs with simpliﬁed/ﬁxed dosing regimens and limited
monitoring, placing high value on the convenience of the treatment
[26,27]. However, elsewhere patients ranked convenience as insignif-
icant compared to risks of bleeding or thrombosis, suggesting they
placed high value on VKA treatment and the associated monitoring
[28]. Importantly, much of this research was undertaken prior to the
widespread availability of DOACs and the regimes presented to patients
were hypothetical, therefore preferences may not translate into real
practice.
The Switching Study is an ongoing programme of work evaluating
the association between health and medication beliefs with adherence
to anticoagulation, the protocol has been published previously [29]. In
this sub-study, the real-world experiences of patients switched from
VKA to DOAC were explored following a minimum of 12 months
treatment with a DOAC through focus groups. The aims of this sub-
study were to investigate: the status of VKAs in comparison to their
other medication prior to the switch owing to the high degree of
monitoring and engagement with services associated with VKAs, if
there was any change in the perceived status of anticoagulation post
switch owing to the minimal routine management and engagement
with services, adherence to DOAC 1 year or more after initiating
therapy and patient preferences for service provision in the context of
anticoagulation.
2. Methods
Patients recruited into the Switching Study who had been switched
from VKA to DOAC due to low TTR prior to November 2015 and
therefore would have been prescribed it for greater than one year at the
time of the focus group, were invited to participate in a focus groups at
the anticoagulation clinic they were treated. In brief, as part of the
broader study patients were seen in clinic at the point of switching to
DOAC. This approximately 45-minute consultation explored issues
surrounding VKA use; patients were counselled on DOACs and con-
sented. Patients had a further 3 clinic appointments on average lasting
15 to 20 min at months 1, 2 and 12 after switching. The South London
model of care states patients would initiate DOAC therapy in secondary
care and be discharged to primary care after 3 months.
Eligible patients for this focus group sub-study were sent invitation
letters and asked to indicate their intention to participate by returning a
response form or by contacting a member of the research team. A target
of 8 participants for each focus group was set as this is a manageable
number for conducting focus groups whilst also allowing for a range of
patients and views to assess [30]. In November 2016, four focus groups
were conducted, across the two anticoagulation clinics at King's College
Hospital NHS Foundation Trust, London: Denmark Hill (DH) and
Princess Royal University Hospital (PRUH) sites (Fig. 1). A target
duration of 90-minutes was set for each session. Patients were oﬀered a
retail voucher worth £30 for their participation. The focus groups ex-
plored four themes.
1. The value patients placed on VKAs compared to other medications
prescribed.
2. Experiences with DOAC therapy, particularly post discharge from
the anticoagulation clinic.
3. Adherence to DOACs following discharge from the anticoagulation
clinic.
4. Patient preferences for long-term anticoagulation monitoring and
service provision.
The sessions were conducted by an anticoagulation pharmacist and
Fig. 1. Focus group pathway.
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psychologist as facilitators. Patients were unfamiliar with the facil-
itators, who were not involved in their care, and participants were
unaware the facilitators were health professionals with expertise in
anticoagulation. All facilitators had experience in conducting focus
groups and/or had received training prior to this research. There was 1
female and 1 male facilitator in each session. Anticoagulation specia-
lists facilitated so that erroneous views expressed by participants re-
garding anticoagulation, that might have been believed by others could
be corrected at the end of the session. Patients were told the researchers
were interested in their individual experiences and views to help im-
prove future services, that it was in no way a test and their comments
would not aﬀect their future care.
All sessions were audio recorded, transcribed verbatim and entered
into NVivo qualitative data analysis Software; QSR International Pty Ltd.
Version 11, 2015 for qualitative analysis. A framework analysis meth-
odology was employed, which is a form of thematic analysis providing
descriptive explanations of data in relation to themes extracted from
that data [31]. Transcripts were coded by JKBA and a coding manual
generated which was then validated by JC. As part of the validation
process, the validator was to bring to light any un-coded themes and the
coding process would be repeated to ensure saturation of the data. Each
coder operated independently however on completion the coders dis-
cussed the data and coding manual to provide quality assurance of the
analysis and ensure there were no inconsistencies. Once validated, a
framework matrix was developed and themes were extracted.
This study was reviewed and approved by the London-Dulwich
Research Ethics Committee (13/LO/1468) and King's College Hospital
NHS Foundation Trust research and development (KCH14-111).
3. Results
3.1. Participants
Invitations were sent to 108 patients of whom 30 (28%) declared
their intention to be considered (Fig. 1). As only one participant at-
tended the DH VTE session, it was conducted as a semi-structured in-
terview using the same topic guide as for the focus groups. For patient
characteristics including stroke and bleeding risk [32,33], see Table 1.
Amongst the AF cohort, only patient AF 9 had a history of stroke, all
other AF patients were prescribed anticoagulation for primary pre-
vention of stroke.
The transcripts were coded by JKBA and during validation no
themes or codes were added by JC, indicating saturation of the data.
3.2. Qualitative themes
Six key themes emerged from the analysis:
• Indication Speciﬁc Anticoagulation Prioritisation
• VKAs: A Necessary Inconvenience
• DOACs: the Anticoagulant of Choice
• Monitoring DOAC therapy
• Adherence to DOACs
• Provision for Access to Specialist Services Long Term
Further illustrative examples of participant responses can be seen in
supplementary materials.
3.2.1. Indication speciﬁc anticoagulation prioritisation
When asked where warfarin ranked amongst their medications, AF
patients generally reported it was no more important than most of their
medications, that VKAs were one of several medications needed to
manage their cardiac condition. Although frequent testing and dose
changes were considered inconvenient, the proﬁle of VKAs was not
raised in these patient's minds relative to other therapies.
“I think that they are quite important, you know, tablets that I take
for my heart and the angina and all that. It is important to take them
all. It's just that I think with warfarin it's just a pain, yes, in the way
it works, you know.” Patient AF-2
Conversely, VTE patients claimed to prioritise VKA therapy. Having
experienced at least one thrombotic event previously, relying on VKAs
to treat and prevent further thrombi.
“Um. Yes. Probably, because the whole sort of concept of having a
blood clot and what can happen is quite sort of frightening, yeah so
to me it [warfarin] was more important.” Patient VTE-1
“Yeah, yeah because I am very, very concerned. If you miss it, it
means you are going to get a clot. And I don't know if it has anything
to do with it, because my thigh was swollen and it was also coming
up to my lungs. And that also frightened me. So, when they said
warfarin, I made sure that I took it.” Patient VTE-4
3.2.2. VKAs: a necessary inconvenience
All patients recognised the need for long-term anticoagulation, with
no patient questioning the necessity of their treatment; patients did
however express complaints about their treatment. The main objection
to VKAs was the cumbersome nature of therapy. All patients had low
TTR at the point of switching, requiring more tests than the average
patient. Testing was the most frequently cited complaint. Testing was
particularly diﬃcult for those in employment who either disrupted
work to get tested or delay their testing to satisfy their work commit-
ments. Proximity to testing centres was a signiﬁcant issue for some
patients who travelled some distance to be tested. There were also
patients who reported having to wait in the blood test facility for long
periods of time.
“I appreciate the things that can happen with taking warfarin, be-
cause it's like a preventative for irregular heartbeat and all that…
And take it at a certain time, your intake of food is rather restricted
and all that… a certain amount always. And I'm very glad I missed
that, because I was told that every time I take blood tests I'm 30%
over or under” Patient AF-3
Table 1
Summary of participant characteristics> 1 year into DOAC therapy.
Code
name
Site Age Gender Treatment CHA2DS2VASc HAS-
BLED
Duration
of VKA
Therapy
(weeks)
VTE 1 PRUH 63 Female Rivaroxaban N/A 1 66
VTE 2 PRUH 66 Male Rivaroxaban N/A 2 194
VTE 3 PRUH 44 Male Rivaroxaban N/A 2 112
VTE 4 PRUH 77 Male Apixaban N/A 2 51
VTE 5 DH 54 Male Rivaroxaban N/A 1 102
AF 1 PRUH 74 Male Apixaban 4 4 105
AF 2 PRUH 59 Female Apixaban 4 3 45
AF 3 PRUH 66 Male Apixaban 2 3 20
AF 4 PRUH 77 Male Rivaroxaban 3 2 28
AF 5 PRUH 78 Male Apixaban 5 4 264
AF 6 PRUH 71 Male Apixaban 3 3 146
AF 7 PRUH 64 Female Rivaroxaban 3 1 223
AF 8 DH 70 Male Rivaroxaban 2 3 76
AF 9 DH 69 Male Rivaroxaban 4 3 254
AF 10 DH 89 Male Apixaban 3 2 307
AF 11 DH 72 Female Apixaban 4 3 166
AF 12 DH 80 Female Apixaban 3 3 78
AF 13 DH 53 Female Apixaban 3 1 26
AF 14 DH 60 Male Apixaban 1 3 25
AF 15 DH 57 Female Rivaroxaban 4 3 278
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3.2.3. Monitoring DOAC therapy
Patients appeared to struggle with the paradigm shift moving from
VKAs to DOACs, speciﬁcally regarding the nature of oral antic-
oagulation monitoring. Many found it diﬃcult to understand why VKAs
needed monitoring so frequently and DOACs did not. Within this was
also an expectation that such monitoring would indicate treatment ef-
ﬁcacy; despite understanding the key parameter being reviewed with
DOACs was renal function, for many this seemed incongruous with
what they previously knew of anticoagulation. Patients reported they
resorted to trusting health professionals knew what they were doing
and they would not be at a high thrombotic risk.
“I thought well, why were all these checks necessary when I was
taking warfarin? And why now do I go for a blood test once every six
months? And I thought, well, what's happening in there now that
happened with the warfarin? How does it regulate itself auto-
matically? If the clotting agent or whatever it was going up and
down like crazy with warfarin, but it wasn't with apixaban […]”
Patient AF-6
Expectations and preferences regarding monitoring DOACs varied
largely depending on their indication for anticoagulation. VTE patients
were eager for eﬃcacy monitoring to provide reassurance regarding
thrombotic risk. Tests akin to INR were frequently referred to as being
desirable. They felt uneasy about not knowing how their blood was
clotting and the key monitoring taking place was related to renal
function. By contrast, AF patients key concern with regards to mon-
itoring was to ensure that therapy was safe, with low risk of adverse
eﬀects and that they would be on the correct dose.
“I mean I actually understand that the blood test that you have done
is nothing to do with INR, it's a kidney function test I think because
it's processed through the kidneys. So again, there's no INR about it
but there is that kind of feeling that you know; how do you know?
Even if someone said, have your INR done once a year, I would be
happy with that.” Patient VTE- 1
3.2.4. DOACs as the anticoagulant of choice
Despite concerns surrounding monitoring, patients emphatically
preferred DOACs. Reasons were often presented in context of hin-
drances with VKAs such as frequent testing, dose changes, dietary re-
strictions and alcohol interactions. Furthermore, some patients de-
scribed anxiety from ﬂuctuating INRs and were glad this was no longer
a feature of their treatment.
“It helps a lot, it helps a lot, it gives you the freedom, because as you
were saying you are restricted in eating your greens and those sorts
of things. But with this one you can eat whatever you want. I haven't
gone to drinking yet, but probably there's room for me to drink.”
Patient VTE-4
When asked whether they wished to return to VKAs treatment, no
patient indicated they would. However, patients acknowledged that
VKAs were no less eﬀective than DOACs, stating “it just didn't seem to
work for them”, or they “just couldn't get it to regulate”.
3.2.5. Adherence to DOACs
Most patients self- reported to be highly adherent to DOACs. Whilst
some claimed emphatically they had never missed a dose, many sug-
gested they might take a dose later than scheduled rather than com-
pletely missing it, whereas previously with VKAs they would have been
hesitant to do so. Some patients utilised multi-dose devices such as pill
boxes to help them keep track of their medication, others used mobile
phone reminders or relied on family members. Most patients reported
DOACs ﬁtted in easily with established medicine taking routines, con-
tributing to their high adherence.
There was agreement that missing a single dose would do little harm
provided it was an isolated incident. It was widely acknowledged that
frequently missed doses would place them at signiﬁcant thrombotic
risk.
3.2.6. Provision for access to specialist services long term
There were an array of responses regarding preferences for long-
term monitoring and follow up. A minority stated that there need not be
any follow up unless there was a clinical need, others preferred an
annual or biennial review with an anticoagulation specialist, whilst a
minority felt this should conducted by a general practitioner (GP).
The majority of participants stated a preference for some form of
long-term follow up to monitor their therapy. Those preferring a spe-
cialist anticoagulation setting did so as they felt that expertise was re-
quired to manage DOACs. Some expressed a lack of conﬁdence in pri-
mary care practitioners eﬀectively managing DOACs. For some this was
due to previous experience with primary care providers related to their
anticoagulation, for others it was based on a perceived ambivalence
from their GP. At the time the focus groups were conducted, several
patients were due their routine renal function monitoring. Some pa-
tients stated that they had not been asked by their GP to have blood
tests, while others who did have tests complained that they were not
informed of the outcome of the blood tests, having no conversation with
their GP about what this means for their anticoagulation therapy for the
upcoming period.
“With the warfarin, they're [GP] spending more time talking to you
about it but when you talk to them about rivaroxaban, it's like,
they'll be standing there, turning the box around and looking at it…
So, when they then start talking to you about it, you're not picking
up conﬁdence in what they're trying to explain to you… I think I
know more about it than he does…Well, with this modern medicine
[DOAC], I've seen him, while I'm talking to him, looking at Google.
Googling up this [drug]…” Patient VTE-5
Furthermore, there was a suggestion that phone access to a dedi-
cated anticoagulant service would be of value in case patients had
questions surrounding their therapy or required advice relating to ad-
verse events. When asked if they were likely to use such a service, many
declared that they would, should they need it and would utilise it as
ﬁrst line rather than contacting their GP.
4. Discussion
This study provides valuable insight into patient experiences fol-
lowing the switch from VKA to DOAC. Focussing on this patient group,
who were switched speciﬁcally due to low TTR is of importance as UK
and European guidance suggests patients with TTR< 65% should be
considered for DOAC therapy [21]. For healthcare providers, there is
therefore an imperative to understand their experiences and tailor
services to address patient needs.
Although experiences regarding diﬃculties in VKA management are
widely known, they nonetheless deserve attention. Frequent testing is
unavoidable in ensuring safe anticoagulation; however, the provision
and setup of testing centres can be addressed. Similar issues have been
raised in research elsewhere [24,25]. Capillary testing is a quick and
easily applicable alternative to venous sampling. Venous sampling is
time consuming for patients, furthermore in those for whom acquiring
venous access is problematic, it can be lengthy and painful [34]. This is
particularly important for elderly populations, which the majority of AF
patients are [35,36]. Similarly, for those who rely on health visitors
attending to the patient in their home, capillary testing may be more
economic and convenient.
The vast majority of patients reported high levels of adherence to
DOACs, with no patient reporting they deliberately omit doses. In most
cases, when missed doses did occur, the remainder of the patient's
medicines were also missed. All patients were prescribed at least one
medication in addition to their anticoagulant. Therefore it is likely that
all participants had some form of established medicines taking routine
J.K. Bartoli- Abdou et al. Thrombosis Research 162 (2018) 62–68
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which would aid adherence, this is consistent with previous research
[17]. To ensure optimal adherence to DOACs in patients prescribed
additional medicines, perhaps eﬀorts should be directed towards ad-
dressing adherence in the context of an entire regime rather than a
single drug. This does not negate addressing knowledge deﬁcits or
patient beliefs surrounding their illness and anticoagulation in the
consultation as this can be vital in ensuring good adherence [25,37].
Furthermore, research demonstrates AF patients value these discussions
when considering anticoagulation [38,39]. It must be noted that pa-
tients were invited to discuss their adherence and no validated ad-
herence measure was used, it is possible that patients may have in-
accurately reported their adherence.
On realising doses had been missed the majority of patients reported
they would take their dose as soon as they realised whilst a minority
stated they would wait until the next scheduled dose. In their antic-
oagulation knowledge questionnaire study, Desteghe and colleagues
found that 57% of DOAC patients did not know how to appropriately
manage missed doses [40]. During initiation it is vital patients are in-
formed of best course of action in these scenarios and that this be re-
inforced at subsequent consultations [41]. A range of techniques were
adopted by participants to aid adherence: mobile phone reminders,
multi-dose devices such as self-ﬁlled dossette boxes to assist keeping
track of what was taken and social support from family members was
also common. This is in keeping with research elsewhere with AF pa-
tients recommending anticoagulation services provide support with
memory aids [39].
It is clear our patients valued anticoagulation diﬀerently depending
on the indication for treatment. Whilst it is tempting to assume that
perceptions regarding a single drug will be similar across diﬀerent
populations, our VTE patients valued and prioritised anticoagulation
more than AF patients. This may be intuitive as the VTE patients ex-
perienced multiple thrombotic events where anticoagulation was the
active treatment. This experience may enable them to recognise the
value of prophylactic anticoagulation more readily. According to the
COM-B model of adherence which suggests that medicines use is a
behaviour inﬂuenced by one's capability to adhere, opportunity to ad-
here and motivation to adhere [42,43]; VTE patients would have re-
latively higher motivation due to their prior experience. Whereas in our
AF sample, only one participant had a history of stroke and therefore
motivation may be lower in patients prescribed anticoagulation for
primary prevention [16,44].
Patients reported concerns regarding the frequency and nature of
monitoring with DOACs in comparison to VKAs. Although all patients
were informed of the rationale for type of monitoring DOACs require and
the diﬀerences with VKAs at initiation, this was either not retained-long
term or was insuﬃcient. Perhaps dedicating time in consultations to
address monitoring both verbally and in writing would be valuable.
Patient expectations with regards to monitoring, i.e. VTE patients ex-
pecting eﬃcacy monitoring and AF patients largely expecting safety
monitoring; aligns signiﬁcantly with the value patients placed on
therapy. Research amongst VTE patients demonstrates that the more
thrombotic experiences the patient has, the greater the anxiety and
perceived risk of further thrombosis [45]. VTE patients were most con-
cerned with preventing thrombosis and wanted tests to inform them their
risk was low. For AF patients who placed lower value on their antic-
oagulation, whilst recognising its necessity, their priority for monitoring
was that treatment did no harm. This replicates previous research ﬁnding
AF patients value anticoagulation safety more than eﬃcacy [46], espe-
cially when made explicitly aware that major bleeding can cause death
[47]. Elsewhere, large variation has been found in AF patient's will-
ingness to accept major bleeding in stroke prevention [48]. Had there
been greater representation of stroke suﬀerers amongst our AF partici-
pants this ﬁnding may have been diﬀerent. However, this dichotomy
between AF and VTE patients is of value when considering that a large
proportion of anticoagulated AF patients are being treated for primary
prevention and will not have experienced a thrombotic event.
A large proportion of patients derived conﬁdence from being man-
aged long-term by a specialist anticoagulation clinic rather than in
primary care, even though the monitoring required can be handled in
primary care. This seemed based on the perception DOACs as “new”
and knowledge about them is not mainstream, as well as negative ex-
periences amongst some participants with GPs around DOACs. As up-
take of DOACs increases, models of care are more likely to utilise pri-
mary care far more than with VKAs. There is therefore a pressing need
that primary care clinicians become upskilled with respect to DOACs.
Research demonstrates that both primary and secondary care clinicians
were unable to recognise DOACs as anticoagulants or identify risks
associated with them [49,50]. Furthermore, in secondary care, drug
related problems with DOACs have been found to be signiﬁcantly high,
a key factor being limited knowledge amongst clinicians [51]. Patients
reporting they would preferentially contact the anticoagulation clinic
over their GP for anticoagulant related advice suggests that provisions
should be made for patients to consult specialists should the need arise.
The ﬁndings of this research are to be incorporated into a sub-
sequent sub-study of the Switching Study. Using the evidence base
generated from the focus groups as well as other aspects of this body of
research, an intervention to support patients who are newly switched
from long-term VKAs to long-term DOACs for SPAF or secondary pre-
vention of VTE will be piloted.
5. Conclusion
One year on from switching from VKAs to DOACs due to low TTR,
patients reported to be adherent to DOAC therapy. Whilst VTE patients
placed greater value on anticoagulation, this did not result in a greater
level of adherence. Patients derived conﬁdence in being managed by
specialist services and largely wished to have long-term monitoring
through that specialist service rather than through primary care, al-
though their expectations for what monitoring would involve varied.
6. Limitations
This study only examined experiences of those with a history of VKA
use. Although some ﬁndings such as the value patients place on antic-
oagulation may be applicable, not all ﬁndings may translate to antic-
oagulation naïve patients prescribed DOACs. Furthermore, our sample
size was small and our participants were a self-selecting group of pa-
tients who volunteered to participate. It is possible that our participants
may not be representative of the overall anticoagulated population.
Author contributions
Data collection was conducted by JKBA, JPP and VA. Data analysis
was conducted by JKBA and JC. This manuscript was drafted by JKBA,
was subsequently revised by JPP and VA and reviewed by all other
authors.
Disclosures
Professor Arya has received honoraria for lectures and travel from
Bayer, Boehringer Ingelheim and Pﬁzer, and awards for investigator
sponsored research from Bayer and Covidien. Dr Auyeung and Dr J.P.
Patel have received investigator initiated research funding from Bayer.
Dr Vadher has received travel grants and event sponsorship from
Boehringer-Ingelheim and Bayer. Dr Roberts has received speaker fees
and a travel grant from Bayer. Dr R. Patel has received honoraria from
Bayer, Boehringer-Ingelheim, Daiichi-Sankyo and BMS- Pﬁzer. Alison
Brown has received a travel grant from Daiichi-Sankyo. John Bartoli-
Abdou and Jacob Crawshaw have no disclosures to declare.
J.K. Bartoli- Abdou et al. Thrombosis Research 162 (2018) 62–68
66
Acknowledgements
The Switching Study is funded by an investigator initiated grant
from Bayer PLC.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2017.12.021.
References
[1] D. Baker, B. Wilsmore, S. Narasimhan, Adoption of direct oral anticoagulants for
stroke prevention in atrial ﬁbrillation, Intern. Med. J. 46 (2016) 792–797, http://
dx.doi.org/10.1111/imj.13088.
[2] S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh,
J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu,
R. Diaz, B.S. Lewis, H. Darius, H.-C. Diener, C.D. Joyner, L. Wallentin, Dabigatran
versus warfarin in patients with atrial ﬁbrillation, N. Engl. J. Med. 361 (2009)
1139–1151, http://dx.doi.org/10.1056/NEJMoa0905561.
[3] S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson,
D. Baanstra, J. Schnee, S.Z. Goldhaber, Dabigatran versus warfarin in the treatment
of acute venous thromboembolism, N. Engl. J. Med. 361 (2009) 2342–2352, http://
dx.doi.org/10.1056/NEJMoa0906598.
[4] S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, D. Baanstra,
A.M. Kvamme, J. Friedman, P. Mismetti, S.Z. Goldhaber, Extended use of dabiga-
tran, warfarin, or placebo in venous thromboembolism, N. Engl. J. Med. 368 (2013)
709–718, http://dx.doi.org/10.1056/NEJMoa1113697.
[5] G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson,
U. Masiukiewicz, R. Pak, J. Thompson, G.E. Raskob, J.I. Weitz, Oral apixaban for
the treatment of acute venous thromboembolism, N. Engl. J. Med. 369 (2013)
799–808, http://dx.doi.org/10.1056/NEJMoa1302507.
[6] G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, A. Porcari,
G.E. Raskob, J.I. Weitz, Apixaban for extended treatment of venous thromboem-
bolism, N. Engl. J. Med. 368 (2013) 699–708, http://dx.doi.org/10.1056/
NEJMoa1207541.
[7] C.B. Granger, J.H. Alexander, J.J.V. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna,
H. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton,
J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto,
A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis,
J. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W.A. Verheugt, J. Zhu, L. Wallentin,
Apixaban versus warfarin in patients with atrial ﬁbrillation, N. Engl. J. Med. 365
(2011) 981–992, http://dx.doi.org/10.1056/NEJMoa1107039.
[8] The EINSTEIN Investigators, Oral rivaroxaban for symptomatic venous throm-
boembolism, N. Engl. J. Med. 363 (2010) 2499–2510, http://dx.doi.org/10.1056/
NEJMoa1007903.
[9] The EINSTEIN–PE Investigators, Oral rivaroxaban for the treatment of symptomatic
pulmonary embolism, N. Engl. J. Med. 366 (2012) 1287–1297, http://dx.doi.org/
10.1056/NEJMoa1113572.
[10] M.R. Patel, K.W. Mahaﬀey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt,
J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini,
S.D. Berkowitz, K.A.A. Fox, R.M. Caliﬀ, Rivaroxaban versus warfarin in nonvalvular
atrial ﬁbrillation, N. Engl. J. Med. 365 (2011) 883–891, http://dx.doi.org/10.1056/
NEJMoa1009638.
[11] R.P. Giugliano, C.T. Ruﬀ, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin,
A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Spinar, W. Ruzyllo, M. Ruda,
Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok,
M. Mercuri, E.M. Antman, E.A.-T. Investigators, Edoxaban versus warfarin in pa-
tients with atrial ﬁbrillation, N. Engl. J. Med. 369 (2013) 2093–2104, http://dx.doi.
org/10.1056/NEJMoa1310907.
[12] V.T.E.I. Hokusai, H.R. Buller, H. Decousus, M.A. Grosso, M. Mercuri, S. Middeldorp,
M.H. Prins, G.E. Raskob, S.M. Schellong, L. Schwocho, A. Segers, M. Shi,
P. Verhamme, P. Wells, Edoxaban versus warfarin for the treatment of symptomatic
venous thromboembolism, N. Engl. J. Med. 369 (2013) 1406–1415, http://dx.doi.
org/10.1056/NEJMoa1306638.
[13] A. Amin, J.C. Marrs, Direct oral anticoagulants for the management of throm-
boembolic disorders: the importance of adherence and persistence in achieving
beneﬁcial outcomes, Clin Appl Thromb Hemost. 22 (7) (2016) 605–616, http://dx.
doi.org/10.1177/1076029615601492 Epub 2015 Aug 27.
[14] H. Ten Cate, New oral anticoagulants: discussion on monitoring and adherence
should start now, Thromb. J. 11 (2013) 8-9560-11-8, http://dx.doi.org/10.1186/
1477-9560-11-8.
[15] A. Di Minno, G. Spadarella, A. Tufano, D. Prisco, G. Di Minno, Ensuring medication
adherence with direct oral anticoagulant drugs: lessons from adherence with vi-
tamin K antagonists (VKAs), Thromb. Res. 133 (2014) 699–704, http://dx.doi.org/
10.1016/j.thromres.2014.01.016.
[16] J.K. Abdou, V. Auyeung, J.P. Patel, R. Arya, Adherence to long-term antic-
oagulation treatment, what is known and what the future might hold, Br. J.
Haematol. 174 (1) (2016) 30–42 https://doi.org/10.1111/bjh.14134.
[17] L.A. Castellucci, J. Shaw, K. van der Salm, P. Erkens, G. Le Gal, W. Petrcich,
M. Carrier, Self-reported adherence to anticoagulation and its determinants using
the Morisky medication adherence scale, Thromb. Res. 136 (2015) 727–731, http://
dx.doi.org/10.1016/j.thromres.2015.07.007.
[18] X. Yao, N.S. Abraham, G.C. Alexander, W. Crown, V.M. Montori,
L.R. Sangaralingham, B.J. Gersh, N.D. Shah, P.A. Noseworthy, Eﬀect of adherence
to oral anticoagulants on risk of stroke and major bleeding among patients with
atrial ﬁbrillation, J. Am. Heart Assoc. 5 (2016), http://dx.doi.org/10.1161/JAHA.
115.003074 (10.1161/JAHA.115.003074).
[19] O. Hanon, E. Chaussade, P. Gueranger, E. Gruson, S. Bonan, A. Gay, Patient-re-
ported treatment satisfaction with rivaroxaban for stroke prevention in atrial ﬁ-
brillation. A French observational study, the SAFARI study, PLoS One 11 (2016)
e0166218, http://dx.doi.org/10.1371/journal.pone.0166218.
[20] NICE, Atrial Fibrillation: The Management of Atrial Fibrillation. National Institute
of Health & Care Excellence. CG 180, https://www.nice.org.uk/guidance/cg180,
(2014).
[21] H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H.C. Diener, W. Hacke,
J. Oldgren, P. Sinnaeve, A.J. Camm, P. Kirchhof, Advisors. Updated European Heart
Rhythm Association practical guide on the use of non-vitamin K antagonist antic-
oagulants in patients with non-valvular atrial ﬁbrillation. Europace: European pa-
cing, arrhythmias, and cardiac electrophysiology, Journal of the working groups on
cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European
Society of Cardiology 17 (2015) 1467–1507, http://dx.doi.org/10.1093/europace/
euv309.
[22] G.C. Dantas, B.V. Thompson, J.A. Manson, C.S. Tracy, R.E. Upshur, Patients' per-
spectives on taking warfarin: qualitative study in family practice, BMC Fam. Pract. 5
(2004) 15, http://dx.doi.org/10.1186/1471-2296-5-15.
[23] D. Wild, M. Murray, C. Donatti, Patient perspectives on taking vitamin K antago-
nists: a qualitative study in the UK, USA and Spain, Expert Review of
Pharmacoeconomics & Outcomes Research. 9 (2009) 467–474, http://dx.doi.org/
10.1586/erp.09.48.
[24] Y.S. Kauﬀman, A.E. Schroeder, D.M. Witt, Patient speciﬁc factors inﬂuencing ad-
herence to INR monitoring, Pharmacotherapy: The Journal of Human
Pharmacology and Drug Therapy. 35 (2015) 740–747, http://dx.doi.org/10.1002/
phar.1616.
[25] G. Mas Dalmau, E. Sant Arderiu, M.B. Enfedaque Montes, I. Solà, S. Pequeño Saco,
Coello P. Alonso, Patients' and physicians' perceptions and attitudes about oral
anticoagulation and atrial ﬁbrillation: a qualitative systematic review, BMC Fam.
Pract. 18 (2017) 3, http://dx.doi.org/10.1186/s12875-016-0574-0.
[26] M. Moia, L.G. Mantovani, M. Carpenedo, L. Scalone, M.S. Monzini, G. Cesana,
P.M. Mannucci, Patient preferences and willingness to pay for diﬀerent options of
anticoagulant therapy, Intern. Emerg. Med. 8 (2013) 237–243, http://dx.doi.org/
10.1007/s11739-012-0844-3.
[27] B. Bottger, I.M. Thate-Waschke, R. Bauersachs, T. Kohlmann, T. Wilke, Preferences
for anticoagulation therapy in atrial ﬁbrillation: the patients' view, J. Thromb.
Thrombolysis 40 (2015) 406–415, http://dx.doi.org/10.1007/s11239-015-1263-x.
[28] P. Ghijben, E. Lancsar, S. Zavarsek, Preferences for oral anticoagulants in atrial
ﬁbrillation: a best-best discrete choice experiment, PharmacoEconomics 32 (2014)
1115–1127, http://dx.doi.org/10.1007/s40273-014-0188-0.
[29] V. Auyeung, J.P. Patel, J.K. Abdou, B. Vadher, L. Bonner, A. Brown, L.N. Roberts,
R.K. Patel, R. Arya, Anticoagulated patient's perception of their illness, their beliefs
about the anticoagulant therapy prescribed and the relationship with adherence:
impact of novel oral anticoagulant therapy — study protocol for the switching
study: a prospective cohort study, BMC Hematology 16 (2016) 22-016-0061-
9(eCollection 2016), https://doi.org/10.1186/s12878-016-0061-9.
[30] P.I. Fusch, L.R. Ness, Are we there yet? Data saturation in qualitative research,
Qual. Rep. 20 (2015) 1408–1416.
[31] N.K. Gale, G. Heath, E. Cameron, S. Rashid, S. Redwood, Using the framework
method for the analysis of qualitative data in multi-disciplinary health research,
BMC Med. Res. Methodol. 13 (2013) 117, http://dx.doi.org/10.1186/1471-2288-
13-117.
[32] R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, G.Y. Lip, A novel user-
friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with
atrial ﬁbrillation: the Euro Heart Survey, Chest 138 (2010) 1093–1100, http://dx.
doi.org/10.1378/chest.10-0134.
[33] G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns, Reﬁning clinical risk
stratiﬁcation for predicting stroke and thromboembolism in atrial ﬁbrillation using
a novel risk factor-based approach: the euro heart survey on atrial ﬁbrillation, Chest
137 (2010) 263–272, http://dx.doi.org/10.1378/chest.09-1584.
[34] K. Woods, J.D. Douketis, T. Schnurr, K. Kinnon, P. Powers, M.A. Crowther, Patient
preferences for capillary vs. venous INR determination in an anticoagulation clinic:
a randomized controlled trial, Thromb. Res. 114 (2004) 161–165, http://dx.doi.
org/10.1016/j.thromres.2004.05.013.
[35] R.C. Davis, F.D.R. Hobbs, J.E. Kenkre, A.K. Roalfe, R. Iles, G.Y.H. Lip, M.K. Davies,
Prevalence of atrial ﬁbrillation in the general population and in high-risk groups:
the ECHOES study, Europace 14 (2012) 1553–1559.
[36] S. Stewart, C.L. Hart, D.J. Hole, McMurray JJV, Population Prevalence, Incidence,
and Predictors of Atrial Fibrillation in the Renfrew/Paisley Study, (2001), pp.
516–521.
[37] R. Horne, L.D. Cameron, H. Leventhal (Eds.), Treatment Perceptions and Self-reg-
ulation, New York, Taylor & Francis, Inc, 2002, pp. 138–153.
[38] C. Borg Xuereb, R.L. Shaw, D.A. Lane, Patients' and physicians' experiences of atrial
ﬁbrillation consultations and anticoagulation decision-making: a multi-perspective
IPA design, Psychol. Health 31 (2016) 436–455, http://dx.doi.org/10.1080/
08870446.2015.1116534.
[39] D.E. Clarkesmith, G.Y.H. Lip, D.A. Lane, Patients' experiences of atrial ﬁbrillation
and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational
needs: a qualitative study, Thromb. Res. 153 (2016) 19–27, http://dx.doi.org/10.
1016/j.thromres.2017.03.002.
J.K. Bartoli- Abdou et al. Thrombosis Research 162 (2018) 62–68
67
[40] L. Desteghe, L. Engelhard, Z. Raymaekers, K. Kluts, J. Vijgen, D. Dilling-Boer,
P. Koopman, J. Schurmans, P. Dendale, H. Heidbuchel, Knowledge gaps in patients
with atrial ﬁbrillation revealed by a new validated knowledge questionnaire, Int. J.
Cardiol. 223 (2016) 906–914, http://dx.doi.org/10.1016/j.ijcard.2016.08.303.
[41] T.M. Brown, K. Siu, D. Walker, M. Pladevall-Vila, S. Sander, M. Mordin,
Development of a conceptual model of adherence to oral anticoagulants to reduce
risk of stroke in patients with atrial ﬁbrillation, JMCP 18 (2012) 351–362, http://
dx.doi.org/10.18553/jmcp.2012.18.5.351.
[42] C. Jackson, L. Eliasson, N. Barber, J. Weinman, Applying COM-B to medication
adherence: a suggested framework for research and interventions, The European
Health Psychologist. 16 (2014) 7–17.
[43] S. Michie, M.M. van Stralen, R. West, The behaviour change wheel: a new method
for characterising and designing behaviour change interventions, Implementation
science: IS. 6 (2011) 42-5908-6-42, http://dx.doi.org/10.1186/1748-5908-6-42.
[44] P. Kardas, P. Lewek, M. Matyjaszczyk, Determinants of patient adherence: a review
of systematic reviews, Front. Pharmacol. 4 (2013), http://dx.doi.org/10.3389/
fphar.2013.00091.
[45] A.A. Kaptein, I.M. van Korlaar, L.D. Cameron, C.Y. Vossen, F.J. van der Meer,
F.R. Rosendaal, Using the common-sense model to predict risk perception and
disease-related worry in individuals at increased risk for venous thrombosis, Health
Psychol. 26 (2007) 807–812, http://dx.doi.org/10.1037/0278-6133.26.6.807.
[46] J.G. Andrade, A.D. Krahn, A.C. Skanes, D. Purdham, A. Ciaccia, S. Connors, Values
and preferences of physicians and patients with Nonvalvular atrial ﬁbrillation who
receive oral anticoagulation therapy for stroke prevention, The Canadian Journal of
Cardiology. 32 (2016) 747–753, http://dx.doi.org/10.1016/j.cjca.2015.09.023.
[47] S. Fatima, A. Holbrook, S. Schulman, S. Park, S. Troyan, G. Curnew, Development
and validation of a decision aid for choosing among antithrombotic agents for atrial
ﬁbrillation, Thromb. Res. 145 (2016) 143–148, http://dx.doi.org/10.1016/j.
thromres.2016.06.015.
[48] S. LaHaye, S. Regpala, S. Lacombe, M. Sharma, S. Gibbens, D. Ball, K. Francis,
Evaluation of patients' attitudes towards stroke prevention and bleeding risk in
atrial ﬁbrillation, Thromb. Haemost. 111 (2014) 465–473, http://dx.doi.org/10.
1160/TH13-05-0424.
[49] A. Olaiya, B. Lurie, B. Watt, L. McDonald, M. Greaves, H.G. Watson, An observa-
tional study of direct oral anticoagulant awareness indicating inadequate recogni-
tion with potential for patient harm, J. Thromb. Haemost. 14 (2016) 987–990,
http://dx.doi.org/10.1111/jth.13288.
[50] G. Arepally, K.A. Bauer, D.L. Bhatt, G.J. Merli, G.V. Naccarelli, R.D. Carter,
R.B. Karcher, C.A. Berry, K.L. Keaton, S.A. Stowell, The use of antithrombotic
therapies in the prevention and treatment of arterial and venous thrombosis: a
survey of current knowledge and practice supporting the need for clinical educa-
tion, Critical Pathways in Cardiology. 9 (2010) 41–48, http://dx.doi.org/10.1097/
HPC.0b013e3181d24562.
[51] M. Viprey, R. Jeannin, V. Piriou, P. Chevalier, C. Michel, G. Aulagner, J. Berthiller,
X. Armoiry, Prevalence of drug-related problems associated with direct oral antic-
oagulants in hospitalized patients: a multicenter, cross-sectional study, J. Clin.
Pharm. Ther. 42 (2017) 58–63, http://dx.doi.org/10.1111/jcpt.12473.
J.K. Bartoli- Abdou et al. Thrombosis Research 162 (2018) 62–68
68
